scholarly article | Q13442814 |
P356 | DOI | 10.1111/APT.13977 |
P698 | PubMed publication ID | 28252185 |
P50 | author | Mario Pirisi | Q53754880 |
James R M Black | Q85231674 | ||
Clarence Yen | Q88032075 | ||
David J. Pinato | Q88654157 | ||
Jessica Howell | Q89393587 | ||
P2093 | author name string | R Sharma | |
C Ferrari | |||
M Kudo | |||
T Arizumi | |||
J-W Park | |||
D Bettinger | |||
M E Burlone | |||
R Thimme | |||
R Ramaswami | |||
L Sellers | |||
A Gibbin | |||
G Guaschino | |||
P2860 | cites work | Pathological bacterial translocation in liver cirrhosis | Q26824138 |
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
Hepatocellular carcinoma | Q29615841 | ||
Microbiota-liver axis in hepatic disease. | Q33855414 | ||
Altered profile of human gut microbiome is associated with cirrhosis and its complications | Q35077209 | ||
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib | Q35583678 | ||
Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors | Q35685574 | ||
Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis | Q35790974 | ||
Toll-like receptor signaling in the liver | Q36477368 | ||
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer | Q36614004 | ||
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma | Q36984575 | ||
Review article: the management of hepatocellular carcinoma | Q37635285 | ||
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 | ||
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis | Q37773059 | ||
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors | Q37937406 | ||
On-target and off-target-based toxicologic effects | Q38053874 | ||
Medical therapies for hepatocellular carcinoma: a critical view of the evidence | Q38059437 | ||
Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy | Q38101885 | ||
Gut-liver immunity. | Q38674310 | ||
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors | Q39019421 | ||
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. | Q39030388 | ||
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. | Q41489415 | ||
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib | Q43411812 | ||
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma | Q45275265 | ||
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. | Q50474760 | ||
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. | Q53097045 | ||
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. | Q53324924 | ||
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. | Q53667125 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | hepatocellular carcinoma | Q1148337 |
P304 | page(s) | 1146-1155 | |
P577 | publication date | 2017-03-02 | |
P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
P1476 | title | On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study | |
P478 | volume | 45 |
Q94475144 | A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression |
Q47954829 | An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma |
Q58793629 | Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis |
Q54521075 | Editorial: sorafenib toxicity, a biomarker of effect? |
Q90302707 | Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC |
Q100725420 | Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study |
Q90674632 | Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib |
Q90451914 | RAF1 Expression is Correlated with HAF, a Parameter of Liver Computed Tomographic Perfusion, and may Predict the Early Therapeutic Response to Sorafenib in Advanced Hepatocellular Carcinoma Patients |
Q90436245 | Review article: systemic treatment of hepatocellular carcinoma |
Q61054484 | Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis |
Q57301434 | Systemic treatments for hepatocellular carcinoma: challenges and future perspectives |
Q57067866 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? |
Q99240029 | Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma |
Q90644228 | Treatment Lines in Hepatocellular Carcinoma |
Q57491231 | Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy |
Search more.